An immunohistochemical germinal center B-cell dark zone signature identifies Burkitt lymphoma and molecular high-grade B-cell lymphomas.

IF 1.9 4区医学 Q2 PATHOLOGY

American journal of clinical pathology Pub Date : 2025-10-04 DOI:10.1093/ajcp/aqaf074

Xiaoxian Zhao, Alexandra Balmaceda, Via S Abiera, Lisa M Rimsza, Desiree Garber, Lynne S Rosenblum, David W Scott, Eric D Hsi

{"title":"An immunohistochemical germinal center B-cell dark zone signature identifies Burkitt lymphoma and molecular high-grade B-cell lymphomas.","authors":"Xiaoxian Zhao, Alexandra Balmaceda, Via S Abiera, Lisa M Rimsza, Desiree Garber, Lynne S Rosenblum, David W Scott, Eric D Hsi","doi":"10.1093/ajcp/aqaf074","DOIUrl":null,"url":null,"abstract":"Objective: We hypothesized that a set of immunohistochemistry (IHC) stains could be used to distinguish Burkitt lymphoma (BL), the quintessential B-cell lymphoma with a germinal center B-cell (GCB) dark zone (DZ) expression signature, from diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). This might also be applicable to high-grade B-cell lymphomas (HGBCLs) with MYC and BCL2 rearrangements (double-hit lymphomas [DHLs]) and triple-hit lymphomas (THLs).Methods: A 5-marker IHC algorithm was designed from gene lists that distinguish physiologic DZ from light zone GCBs.Results: In training and validation cohorts, we distinguished BL from DLBCL, NOS with high sensitivity and specificity. Because DHLs/THLs are enriched for the gene expression DZ signature (DZsig), we evaluated 19 DHLs/THLs and 4 HGBCLs, NOS. Most (83%) cases were IHC DZ. The NanoString DLBCL90 assay was performed on 34 cases to correlate IHC DZ results with the molecular DZsig. The IHC DZ call was significantly associated with the DZsig (P = .0011). The sensitivity and specificity of IHC to recognize DZsig+ cases among DLBCL, NOS and DHLs with BCL2 rearrangements/THLs were 91% and 100%, respectively.Conclusions: The IHC DZ algorithm can support a diagnosis of BL and identifies MYC-BCL2 DHLs/THLs with a molecular DZsig.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"559-566"},"PeriodicalIF":1.9000,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of clinical pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ajcp/aqaf074","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: We hypothesized that a set of immunohistochemistry (IHC) stains could be used to distinguish Burkitt lymphoma (BL), the quintessential B-cell lymphoma with a germinal center B-cell (GCB) dark zone (DZ) expression signature, from diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). This might also be applicable to high-grade B-cell lymphomas (HGBCLs) with MYC and BCL2 rearrangements (double-hit lymphomas [DHLs]) and triple-hit lymphomas (THLs).

Methods: A 5-marker IHC algorithm was designed from gene lists that distinguish physiologic DZ from light zone GCBs.

Results: In training and validation cohorts, we distinguished BL from DLBCL, NOS with high sensitivity and specificity. Because DHLs/THLs are enriched for the gene expression DZ signature (DZsig), we evaluated 19 DHLs/THLs and 4 HGBCLs, NOS. Most (83%) cases were IHC DZ. The NanoString DLBCL90 assay was performed on 34 cases to correlate IHC DZ results with the molecular DZsig. The IHC DZ call was significantly associated with the DZsig (P = .0011). The sensitivity and specificity of IHC to recognize DZsig+ cases among DLBCL, NOS and DHLs with BCL2 rearrangements/THLs were 91% and 100%, respectively.

Conclusions: The IHC DZ algorithm can support a diagnosis of BL and identifies MYC-BCL2 DHLs/THLs with a molecular DZsig.

查看原文本刊更多论文

免疫组织化学生发中心b细胞暗区特征可识别伯基特淋巴瘤和分子级b细胞淋巴瘤。

目的：我们假设一组免疫组织化学（IHC）染色可以用来区分Burkitt淋巴瘤（BL），一种典型的具有生发中心b细胞（GCB）暗区（DZ）表达特征的b细胞淋巴瘤，与弥漫性大b细胞淋巴瘤（DLBCL， NOS）。这可能也适用于MYC和BCL2重排的高级别b细胞淋巴瘤（HGBCLs）（双重打击淋巴瘤[dhl]）和三次打击淋巴瘤（thl）。方法：根据基因表设计5标记免疫组化算法，区分生理性DZ与光区gcb。结果：在培训和验证队列中，我们将BL与DLBCL、NOS区分开来，具有较高的敏感性和特异性。由于dhl / thl富含DZ基因表达特征（DZsig），我们评估了19例dhl / thl和4例hgbcl， NOS。大多数（83%）病例为IHC DZ。对34例患者进行了NanoString DLBCL90检测，以将IHC DZ结果与分子DZsig相关联。IHC DZ呼叫与DZsig显著相关（P = 0.0011）。在合并BCL2重排/ thl的DLBCL、NOS和dhl中，免疫组化识别DZsig+病例的敏感性和特异性分别为91%和100%。结论：IHC DZ算法可支持BL的诊断，并可通过分子DZsig识别MYC-BCL2 dhl / thl。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of clinical pathology 医学-病理学

CiteScore

7.70

自引率

2.90%

发文量

367

审稿时长

3-6 weeks

期刊介绍： The American Journal of Clinical Pathology (AJCP) is the official journal of the American Society for Clinical Pathology and the Academy of Clinical Laboratory Physicians and Scientists. It is a leading international journal for publication of articles concerning novel anatomic pathology and laboratory medicine observations on human disease. AJCP emphasizes articles that focus on the application of evolving technologies for the diagnosis and characterization of diseases and conditions, as well as those that have a direct link toward improving patient care.